The issue is the current environment isn’t exactly conducive to...

The issue is the current environment isn’t exactly conducive to an equity partnership, it could take quite some time to negotiate a deal on favourable terms (ie we don’t want to give up too much equity as that equates to future lost cash flows). If they had done this in 2020-2021 we would have got an amazing deal very quickly

I think we need to finish the LIANA trial first if we wish to attract investors willing to invest on favourable terms for us. This is at least one year away. The company itself has signalled the importance of this trial given they have actually been putting quite a lot of effort into advertising this trial within the medical community recently.

Based on last week’s announcement and the current state of 2RT and the market, I’d say we will be looking at another boring year for Nova Eye Medical. Definitely think EYE will be a huge company in the future with incredibly innovative products (Tom actually hinted at future products based off of iTrack IP in the AGM) but I don’t think we should expect any gains any time soon.

I will wait for the share price to return to 20c before I consider buying more as I personally think the recent appreciation is a bit premature, and a lot of the new buyers will soon be disappointed by the long term nature of an investment in this company.